RHRina Hemi

Rina Hemi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rina Hemi has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Circulating α-Klotho Is Elevated in Breast Cancer and Positively Correlates with IGF-1

    by Shira Ben Neriah, Marana Abboud, Alla Berlin, Rina Hemi, Rona Aks, Shiran Shapira, Ido Wolf, Tami Rubinek

    Breast cancer (BC) is the most commonly diagnosed cancer among women worldwide. Klotho is an anti-aging protein implicated in tumor suppression; however, the relationship between circulating Klotho levels and BC remains unclear. We measured serum Klotho by enzyme-linked immunosorbent assay (ELISA) in 372 participants: 166 patients with BC, 24 patients with ductal carcinoma in situ (DCIS), and 182 controls, and examined its relation to clinicopathological characteristics, including estrogen receptor (ER), progesterone receptor (PR), HER2 and lymph node status, body mass index (BMI), and insulin-like growth factor 1 (IGF-1). Serum Klotho levels were significantly higher in invasive BC and DCIS patients compared with controls (p = 0.003 and p = 0.001, respectively), whereas no significant difference was detected between invasive BC and DCIS. After adjustment for age, Klotho levels remained significantly higher in BC and DCIS patients than in controls. Klotho levels correlated positively with IGF-1 (p = 0.0043), but not with BMI, ER, PR, HER2, or lymph node status. These preliminary findings demonstrate an association between elevated circulating Klotho and BC, as well as a positive relationship between Klotho and IGF-1. Further studies using age-matched cohorts and diagnostic-performance analyses are required to determine whether circulating Klotho has clinical utility as a BC biomarker.

  • Open Access

    Circulating α-Klotho Is Elevated in Breast Cancer and Positively Correlates with IGF-1

    by Shira Ben Neriah, Marana Abboud, Alla Berlin, Rina Hemi, Rona Aks, Shiran Shapira, Ido Wolf, Tami Rubinek

    Breast cancer is the most diagnosed cancer among women worldwide. Klotho is a protein with well-established anti-aging and tumor-suppressive functions, including a documented role in cancer biology such as breast cancer. However, the role of circulating Klotho levels as a biomarker in breast cancer patients remains unclear. We examined serum Klotho in relation to breast cancer and clinicopathological factors, including estrogen receptor (ER), progesterone receptor (PR), HER2 status, lymph node involvement, and body mass index (BMI). A total of 372 individuals were analysed: breast cancer patients (n=166), ductal carcinoma in situ (DCIS, n=24), and controls (n=182). Serum Klotho was measured by enzyme-linked immunosorbent assay (ELISA); comparisons used nonparametric Kruskal-Wallis and Mann-Whitney U tests with Bonferroni correction. Klotho was higher in breast cancer patients than controls (p < 0.01), similar between invasive and in situ disease, and correlated positively with insulin-like growth factor 1 (IGF-1) (p < 0.01), but not with BMI, ER, PR, HER2, or lymph node invasion. These findings raise the possibility that the Klotho–IGF-1 correlation reflects a negative feedback mechanism, whereby IGF-1 may promote Klotho secretion while Klotho may in turn attenuate downstream IGF-1R signalling, a mechanism that warrants further investigation as a potential regulator of IGF-1-driven tumorigenesis.

  • Open Access

    Bone Turnover Markers (CTX and P1NP) Following Low-Carbohydrate and Mediterranean Diet Interventions in Adolescents and Young Adults with Type 1 Diabetes

    by Neriya Levran, Noah Levek, Yael Levy-Shraga, Noah Gruber, Rina Hemi, Ehud Barhod, Liana Tripto-Shkolnik, Arnon Afek, Efrat Monsonego-Ornan, Orit Pinhas-Hamiel

    Background: Impaired bone health is a recognized complication of type 1 diabetes. This study evaluated the effects of low-carbohydrate (LC) and Mediterranean (MED) diets on bone turnover markers in adolescents and young adults. Methods: In a 24-week randomized controlled trial, 40 individuals aged 12–21 years, with type 1 diabetes, were assigned to an LC or MED intervention (20 participants per group). C-terminal telopeptide (CTX) and procollagen type 1 N-terminal propeptide (P1NP) were measured at baseline and 24 weeks. Results: The groups had similar baselines. At 24 weeks, the between-group difference in delta glucose time in range was not statistically significant; median daily carbohydrate intake was 86 g (68–95) in LC and 130 g (102–173) in MED (p < 0.001). Comparing LC to MED, the median BMI z-score was lower (−0.1 [−0.3 to −0.1] vs. 0.0 [−0.1 to −0.1], p = 0.10), and calcium (p = 0.035) and magnesium intakes (p = 0.030) were lower. These associations did not remain statistically significant after false-discovery-rate correction. The median-adjusted alkaline phosphatase level decreased significantly in the LC group (p = 0.009). The median CTX changed following LC from 395 pg/mL (232–591) to 423 pg/mL (289–591) (p = 0.278); and following MED, from 357 pg/mL (244–782) to 296 pg/mL (227–661) (p = 0.245). P1NP changed in LC from 95 ng/mL (68–112) to 88 ng/mL (62–97) (p = 0.056) and in MED from 76 ng/mL (54–198) to 71 ng/mL (55–122) (p = 0.594). Conclusions: Exploratory analyses of bone turnover markers showed insignificant differences following LC and MED diets.


  • Open Access

    The Effect of COVID-19 on Type 1 Diabetes Occurrence among Children and Adolescents: A Multicenter Prospective Observational Cohort Study in Israel

    by Noah Gruber, Liat Brand, Ehud Barhod, Rina Hemi, Yael Lebenthal, Marianna Rachmiel, Tal Kedar, Rachel Shatzman-Steuerman, Rachael Sverdlove, Yaniv Lustig, et al.

    Aim. The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on the pediatric occurrence of type 1 diabetes (T1D) is inconclusive. We aimed to assess associations between seroprevalences of the distinct anti-SARS-CoV-2 antibodies and T1D occurrence in children and adolescents. Methods. This multicenter prospective observational cohort comprised children diagnosed with T1D between October 2020 and July 2022 and unrelated children who performed endocrine tests (control group) in a 1 : 3 ratio. Anti-SARS-CoV-2 antibodies, including anti-S, anti-N, and neutralizing antibodies, were assessed in each group. Results. The cohort included 51 children with T1D and 182 children in the control group. The median (interquartile range) age was 11.4 (8.2, 13.3) years, with 45% being female. Increases were not observed in the seroprevalence of any of the anti-SARS-CoV-2 antibodies among the children with new-onset T1D compared to the control group. Among the T1D group, anti-S seroprevalence was higher among those without diabetic ketoacidosis (DKA) than in those with DKA upon T1D diagnosis (72% vs. 42%, ). After adjustment to vaccination status, this difference was not statistically significant. Additionally, anti-N antibodies and neutralizing antibodies did not differ between the DKA and the non-DKA groups. None of the anti-SARS-CoV-2 antibodies were associated with any of the glycemic parameters. Conclusions. This study is the first to assess several distinct anti-SARS-CoV-2 antibodies in new-onset T1D, and our findings do not support an association between SARS-CoV-2 infection and the occurrence of T1D in children and adolescents. Since autoimmunity may emerge years after a viral infection, we recommend conducting follow-up epidemiological studies to assess whether there is a change in the incidence of T1D following the SARS-CoV-2 pandemic.


  • Open Access

    High physical activity and ovarian reserve: a prospective study of normo-ovulatory professional athletes

    by Netanella Miller, Yael Pasternak, Einat Haikin Herzberger, Hadar Gluska, Chen Dorenstein, Roni Rahav, Rina Hemi, Nahid Zada, Amir Wiser

    Background: This study investigated whether high physical activity affects ovarian reserve in normo-ovulatory, reproductive-age women. Methods: This prospective, observational study compared 31 professional female athletes, with 31 women who did not engage in physical activity. It was conducted 2017–2020 in a tertiary medical center. Normo-ovulatory, professional athletes, ages 20–35 years were recruited from The Wingate Institute—the Israeli National Institute for Sport Excellence. They had high International Physical Activity Questionnaire (IPAQ) scores. Non-physically active women, matched by age and body mass index, were recruited from hospital staff. Women were evaluated for ovarian reserve markers on day 2–5 of the menstrual cycle, including follicular stimulating hormone, antral follicle count, anti-Mullerian hormone and Inhibin B. Results: The average age of the high physical activity group was 29.9 ± 4.2 years and the nonactive group 31.6 ± 4.2 years (p = 0.062). Body mass index of both groups were similar (22.5 ± 5.0 vs. 21.4 ± 2.5, respectively; p = 0.1). No differences were observed with respect to follicle stimulating hormone (p = 0.12) and anti-Mullerian hormone (p = 0.16). A trend towards higher total antral follicle count in the high physical activity group vs. the non-active group (34.5 ± 12.9 vs. 28.1 ± 15.2, p = 0.08) and lower Inhibin B (68.1 ± 36.8 vs. 89.4 ± 46.1, p = 0.05). Menarche age correlated with anti-Mullerian hormone (r = 0.387, p = 0.003), as did total antral follicle count (r = 0.368, p = 0.004). IPAQ scores and basal follicle stimulating hormone levels were negatively correlated (r = − 0.292, p = 0.005). Conclusions: Athletic, normo-ovulatory women have ovarian reserves that are at least as good as those of the general population. As this is the first study examining this issue, it could cautiously reassure women engaged in high physical activity regarding ovarian reserve.


  • Open Access

    The Predictive Value of Serum ACE2 and TMPRSS2 Concentrations in Patients with COVID-19—A Prospective Pilot Study

    by Reut Kassif Lerner, Michal Stein Yeshurun, Rina Hemi, Nahid Zada, Keren Asraf, Ram Doolman, Stefanie W. Benoit, Maria Helena Santos de Oliveira, Giuseppe Lippi, Brandon Michael Henry, et al.

    One of the major challenges for healthcare systems during the Coronavirus-2019 (COVID-19) pandemic was the inability to successfully predict which patients would require mechanical ventilation (MV). Angiotensin-Converting Enzyme 2 (ACE2) and TransMembrane Protease Serine S1 member 2 (TMPRSS2) are enzymes that play crucial roles in SARS-CoV-2 entry into human host cells. However, their predictive value as biomarkers for risk stratification for respiratory deterioration requiring MV has not yet been evaluated. We aimed to evaluate whether serum ACE2 and TMPRSS2 levels are associated with adverse outcomes in COVID-19, and specifically the need for MV. COVID-19 patients admitted to an Israeli tertiary medical center between March--November 2020, were included. Serum samples were obtained shortly after admission (day 0) and again following one week of admission (day 7). ACE2 and TMPRSS2 concentrations were measured with ELISA. Of 72 patients included, 30 (41.6%) ultimately required MV. Serum ACE2 concentrations >7.8 ng/mL at admission were significantly associated with the need for MV (p = 0.036), inotropic support, and renal replacement therapy. In multivariate logistic regression analysis, elevated ACE2 at admission was associated with the need for MV (OR = 7.49; p = 0.014). To conclude, elevated serum ACE2 concentration early in COVID-19 illness correlates with respiratory failure necessitating mechanical ventilation. We suggest that measuring serum ACE2 at admission may be useful for predicting the risk of severe disease.


  • Open Access

    The adipokine FABP4 is a key regulator of neonatal glucose homeostasis

    by Idit Ron, Reut Kassif Lerner, Moran Rathaus, Rinat Livne, Sophie Ron, Ehud Barhod, Rina Hemi, Amit Tirosh, Tzipora Strauss, Keren Ofir, et al.

    During pregnancy, fetal glucose production is suppressed, with rapid activation immediately postpartum. Fatty acid–binding protein 4 (FABP4) was recently demonstrated as a regulator of hepatic glucose production and systemic metabolism in animal models. Here, we studied the role of FABP4 in regulating neonatal glucose hemostasis. Serum samples were collected from pregnant women with normoglycemia or gestational diabetes at term, from the umbilical circulation, and from the newborns within 6 hours of life. The level of FABP4 was higher in the fetal versus maternal circulation, with a further rise in neonates after birth of approximately 3-fold. Neonatal FABP4 inversely correlated with blood glucose, with an approximately 10-fold increase of FABP4 in hypoglycemic neonates. When studied in mice, blood glucose of 12-hour-old WT, Fabp4 –/+ , and Fabp4 –/– littermate mice was 59 ± 13 mg/dL, 50 ± 11 mg/dL, and 43 ± 11 mg/dL, respectively. Similar to our observations in humans, FABP4 levels in WT mouse neonates were approximately 8-fold higher compared with those in adult mice. RNA sequencing of the neonatal liver suggested altered expression of multiple glucagon-regulated pathways in Fabp4 –/– mice. Indeed, Fabp4 –/– liver glycogen was inappropriately intact, despite a marked hypoglycemia, with rapid restoration of normoglycemia upon injection of recombinant FABP4. Our data suggest an important biological role for the adipokine FABP4 in the orchestrated regulation of postnatal glucose metabolism.


  • A Phase I clinical trial of dose-escalated metabolic therapy combined with concomitant radiation therapy in high-grade glioma

    by Keren Porper, Yael Shpatz, Luba Plotkin, Ronit Goldman Pechthold, Alisa Talianski, Colin E. Champ, Orit Furman, Ariel Shimoni-Sebag, Zvi Symon, Uri Amit, et al.

    Background Animal brain-tumor models have demonstrated a synergistic interaction between radiation therapy and a ketogenic diet (KD). Metformin has in-vitro anti-cancer activity, through AMPK activation and mTOR inhibition. We hypothesized that the metabolic stress induced by a KD combined with metformin would enhance radiation’s efficacy. We sought to assess the tolerability and feasibility of this approach. Methods A single-institution phase I clinical trial. Radiotherapy was either 60 or 35 Gy over 6 or 2 weeks, for newly diagnosed and recurrent gliomas, respectively. The dietary intervention consisted of a Modified Atkins Diet (ModAD) supplemented with medium chain triglycerides (MCT). There were three cohorts: Dietary intervention alone, and dietary intervention combined with low-dose or high-dose metformin; all patients received radiotherapy. Factors associated with blood ketone levels were investigated using a mixed-model analysis. Results A total of 13 patients were accrued, median age 61 years, of whom six had newly diagnosed and seven with recurrent disease. All completed radiation therapy; five patients stopped the metabolic intervention early. Metformin 850 mg three-times daily was poorly tolerated. There were no serious adverse events. Ketone levels were associated with dietary factors (ketogenic ratio, p < 0.001), use of metformin (p = 0. 02) and low insulin levels (p = 0.002). Median progression free survival was ten and four months for newly diagnosed and recurrent disease, respectively. Conclusions The intervention was well tolerated. Higher serum ketone levels were associated with both dietary intake and metformin use. The recommended phase II dose is eight weeks of a ModAD combined with 850 mg metformin twice daily.


  • Neurological deficit is predicted by S100B in children after cardiac surgery

    by O. Bar-Yosef, D. Greidinger, M. Iskilova, R. Hemi, T. Tirosh, A. Vardi


  • Open Access

    Anti Müllerian Hormone (AMH) level and expression in mural and cumulus cells in relation to age

    by Alon Kedem, Yuval Yung, Gil M Yerushalmi, Jigal Haas, Ettie Maman, Mirit Hanochi, Rina Hemi, Raoul Orvieto, Jehoshua Dor, Ariel Hourvitz

    Serum AMH is declining with age and is highly associated with ovarian follicular reserve and disordered folliculogenesis. However, the precise role of AMH in the process of human follicular aging has still to be determined. This study investigates AMH level in the follicular fluid (FF) and mRNA expression pattern in cumulus and mural granulosa cells of human ovarian follicles in relation to age. We conducted a prospective study. Sixty-eight women undergoing In vitro fertilization (IVF) treatment were enrolled in the study. We obtained FF, mural and cumulus granulosa cells from large preovulatory follicles (17-20 mm) of 21–35 years old women (n = 40) and 40–45 years old women (n = 28) during oocyte pickup. Higher level of AMH mRNA expression in cumulus cells was observed in the older age group compared to the younger (P <0.01). In accordance with AMH mRNA expression results, FF AMH protein levels were significantly higher in the older group than in the younger group (4.7 ± 1.1 ng\ml and 2.3 ± 0.2 ng\ml respectively, p < 0.002). AMH is highly expressed and secreted from cumulus GCs of advanced age patients. This remarkable correlation between AMH mRNA levels in cumulus cells in respect to age suggests that AMH may be involved in follicular aging process.